Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Cervical: Volrustomig in High Risk Locally Advanced Cervical Cancer
NCT06079671Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of volrustomig in Cervical Cancer (CC), sponsored by AstraZeneca. Started Sep 2023; status: recruiting.
02
Drugs
volrustomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06079671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079671.